Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmuCell Corporation’s quest to keep dairy and beef calves healthy means its SEC disclosures cover everything from colostrum-based antibody sales to the status of Re-Tain, a non-antibiotic mastitis treatment now under FDA review. Whether you’re tracking bio-manufacturing capacity or weighing how feed-price cycles affect demand, the details you need live inside lengthy 10-Ks and a steady stream of 8-Ks. Stock Titan’s AI makes ImmuCell SEC filings explained simply, turning pages of veterinary science into plain-English insights.
Use our platform to move directly from question to answer. Curious about management’s growth assumptions? The ImmuCell annual report 10-K simplified highlights planned fermentation upgrades. Need segment revenue faster? The ImmuCell quarterly earnings report 10-Q filing is summarized line-by-line, and ImmuCell earnings report filing analysis spots margin shifts automatically. Material news such as FDA correspondence appears in an ImmuCell 8-K material events explained snapshot the moment it hits EDGAR.
Insider activity often tells its own story. Our real-time alerts track every ImmuCell insider trading Form 4 transactions, so you’ll see ImmuCell Form 4 insider transactions real-time and understand which directors are buying dip or trimming gains. Drill deeper into governance through the ImmuCell proxy statement executive compensation section, or monitor ImmuCell executive stock transactions Form 4 for fresh context.
Behind each disclosure, Stock Titan layers AI-powered summaries, keyword search across all exhibits, and exportable tables, helping professionals:
- Compare quarter-over-quarter First Defense unit sales
- Monitor capital spending on the new Portland manufacturing suite
- Track regulatory milestones for Re-Tain without reading technical appendices
By understanding ImmuCell SEC documents with AI, you spend fewer hours sifting and more time deciding.
ImmuCell Corporation (ICCC) reported Q3 2025 results. Product sales were $5,506,122 versus $6,011,573 a year ago, and the quarter showed a net loss of $139,748 compared with a loss of $701,690 last year. Gross margin improved to $2,363,098 from $1,583,554 as costs of goods sold declined.
For the nine months ended September 30, 2025, product sales reached $20,018,175 versus $18,742,040, and net income was $1,809,115 versus a loss of $2,671,184 last year. Cash and cash equivalents were $3,886,198. Inventory stood at $9,802,005. Total liabilities were $15,929,282 and stockholders’ equity was $29,800,841.
Capital and financing: During Q3 2025, the company refinanced prior loans into a new $2,327,119 MCB term loan at a fixed 6.5% rate, replacing 7% and 8% debt, removing July 2026 balloon payments and setting monthly payments of $45,637 through the third quarter of 2030.
Concentration: Two customers represented 68% of Q3 product sales. Shares outstanding were 9,045,851 as of October 31, 2025.
ImmuCell Corporation furnished an 8-K announcing it issued a press release with unaudited financial results for the quarter ended September 30, 2025. The disclosure is under Item 2.02 and is expressly stated as furnished, not filed, which limits liability under Section 18.
The filing includes Exhibit 99.1 (press release dated November 13, 2025) and Exhibit 104 (cover page Inline XBRL).
ImmuCell Corp (ICCC)74,277 stock options at an exercise price of $6.10 on November 7, 2025.
The options vest in three equal tranches of 24,759 on the first, second, and third anniversaries of the grant and expire on November 7, 2035. The award will be treated as an incentive stock option to the maximum extent permitted, with the balance as a nonqualified option. Following the grant, the officer beneficially owned 150,260 derivative securities.
ImmuCell (ICCC)$5.90 per share, covering 25,327, 25,327, and 25,329 shares. These options become exercisable on 09/16/2026, 09/16/2027, and 09/16/2028, respectively, and each expires on 09/16/2035. The grant was made in connection with an offer letter outlining the terms of his employment and vests in three increments as shown.
ImmuCell Corporation announced governance changes tied to its CEO transition. Effective November 1, 2025, Olivier te Boekhorst became President and CEO, while Michael F. Brigham stepped down from his roles as President, CEO, Secretary, and Treasurer to serve as Special Advisor to the CEO. On October 29, 2025, the Board expanded from seven to nine directors and elected Mr. te Boekhorst and CFO Timothy C. Fiori as directors. Mr. Fiori was also elected Secretary and Treasurer. Neither executive was appointed to any Board committees.
ImmuCell Corporation appointed Olivier te Boekhorst as President and CEO effective November 1, 2025. He joins from Archimed and previously held senior roles at IDEXX Laboratories and Boston Consulting Group. His compensation package includes a $450,000 base salary, up to $400,000 annual cash bonus tied to financial improvement targets, a $100,000 one-time signing bonus (repayable in certain circumstances), and initial equity awards: a nonqualified option for 76,673 shares at $5.90 and a second grant of up to 85,000 shares (accounting value $250,000). Equity awards vest over three years and accelerate on a Change in Control. The Board will expand and elect him as a director. The existing CEO will transition to Special Advisor during a handover period.
ImmuCell Corporation entered into a Loan Agreement and Promissory Note with Maine Community Bank for total loan proceeds of $2,327,119 at a fixed interest rate of 6.5% per annum. The proceeds were used to pay off an existing Maine Community Bank loan with an outstanding balance of $1,525,852 bearing interest at 7% and a Finance Authority of Maine loan with an outstanding balance of $768,209 bearing interest at 8%, effectively consolidating those obligations into a single loan.
The new loan is secured by a security interest in substantially all of the Company’s assets, and the lender may accelerate repayment if the Company fails to make timely payments or otherwise comply with the loan terms. The Loan Agreement and Promissory Note are filed as Exhibits 10.1 and 10.2, and a related press release is filed as Exhibit 99.1.
FAQ
What is the current stock price of Immucell (ICCC)?
What is the market cap of Immucell (ICCC)?
